Author:
Klassen Stephen A.,Senefeld Jonathon W.
Publisher
Springer Berlin Heidelberg
Reference55 articles.
1. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P et al (2020) Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 22(371):m3939
2. Arnold Egloff SA, Junglen A, Restivo JS, Wongskhaluang M, Martin C, Doshi P et al (2021) Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J Clin Invest 131(20):e151788
3. Avendaño-Solá C, Ramos-Martínez A, Muñez-Rubio E, Ruiz-Antorán B, Malo De Molina R, Torres F et al (2021) A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest 131(20):e152740
4. Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A et al (2021) Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med 27(11):2012–2024
5. Belov A, Huang Y, Villa CH, Whitaker BI, Forshee R, Anderson SA et al (2022) Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. Am J Hematol 97(6):770–779